icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
Sofosbuvir plus velpatasvir for 8 weeks
in patients with acute hepatitis C: Multicenter,
single arm, phase 2 Study The HepNet acute HCV V study

  EASL 2022 June 22-26 London
B. Maasoumy* 1,2,3, P. Ingiliz* 4, C.D. Spinner 5, C. Cordes 6, H-J. Stellbrink 7, J. Schulze zur Wiesch 8,9, S.M. Schneeweiß 10, K. Deterding 11, T. Müller 12, J. Kahlhöfer 2, P. Dörge 2, M. von Karpowitz 13, M.P. Manns 1, H. Wedemeyer # 1, M. Cornberg #,1,2,3,14, for the HepNet Acute HCV V Study Group
* Shared first authorship # Shared last authorship + Corresponding author: Markus Cornberg
1 Hannover Medical School, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 2 German Center for Infection Research (DZIF); HepNet Study-House German Liver Foundation, Hannover, Germany, 3 German Center for Infection Research (DZIF); Partner Site Hannover-Braunschweig, Germany; 4 Zentrum für Infektiologie Berlin-Prenzlauer Berg, Berlin, Germany; 5 Technical University of Munich, School of Medicine, University Hospital Rechts Der Isar, Munich, Germany; 6 Praxis Dr. Cordes, Berlin, Germany; 7 Infectiology Center Hamburg (ICH), Hamburg, Germany; 8 Medical Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 9 German Center for Infection Research (DZIF); Partner Site Hamburg-Lübeck-Borstel-Riems Germany; 10 Praxis Hohenstaufenring, Köln, Germany.; 11 Department of Gastroenterology and Hepatology, University Hospital Essen, 45147 Essen, Germany; 12 Department of Gastroenterology and Hepatology, Charité Campus Virchow-Klinikum (CVK), Berlin, Germany; 13 Institute for Biometry, Hannover Medical School, Germany; 14 Center for Individualized Infection Medicine (CiiM), Hannover, Germany





Treatment was well tolerated. By 12 weeks post-treatment, there was one serious adverse event unrelated to study drug, no patient died during the trial. Six possible or probable drug-related adverse events were documented by week 12 post-treatment. These adverse events were only comprised of mild symptoms like dry or sensitive skin, rash, flatulence, headache and sleep disorder.